No quarterly revenue total was found in Vogenx, Inc.'s SEC filings.
Vogenx, Inc. (VOGX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-384,430
Operating cash flow
$-323,119
Free cash flow
—
EPS
$-0.07
Dividend per share
None
Shares outstanding
14.86M
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VOGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Raleigh, NC
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1903784
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Net income | -$384,430 |
| Diluted EPS | -$0.07 |
| Operating cash flow | -$323,119 |
| Total assets | $1.4M |
| Total liabilities | $3.2M |
| Stockholders' equity | -$1.8M |
| Cash and investments | $193,017 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 9, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 22, 2026 | Sep 21, 2026 |
| 10-Q | Quarterly report | Sep 17, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 19, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 13, 2026 | Aug 13, 2026 |
All 34 Vogenx, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.